Dear Sir or Madam  
My answers are as follow:

1, do you agree that these guidelines apply to all medicines prescribed and /Or dispemsed by Chinese medicine practitioners?

Yes

2, For Chinese herbal medicine prescription writing, do you agree that pinyin or the pharmaceutical name should be used as an alternative to the botanical name, with the addition of Chinese characters where necessary? Is this guideline practical to implement? If you disagree, what alternatives do you suggest?

I agree that Pinyin should be used as an alternative to the botanical name, with the addition of Chinese characters where necessary.

I suggest: the sample: TaiZiShen/ Pseudistellaria heterophylla（ root tuber）/太子参 as this easily refer to Chinese medicine dictionary in China.

3, Do you agree that herbs should be labelled according to their botanical name? if not what alternative do you recommend to address these safety issues and remove ambiguity in labelling?

I do not agree the herbs should be labelled according their botanical name.

I suggest: the sample: TaiZiShen/ Pseudistellaria heterophylla（ root tuber）/太子参 as this easily refer to Chinese medicine dictionary in China.

4, Are the labelling requirements practical to implement?

Yes.

5, Is the required information for prescriptions appropriate?

Yes.

6, Do you agree with the circumstances in which a medicine maybe supplied for self-medication?

No.

7, Do you agree with the limited role of dispensary assistants as outlined in section 5 of the guidelines?

Yes.

8, Are there any additional requirements which should apply to the management of a Chinese herbal dispensary?

No.

9, Does the sample label and prescription assist in understanding the requirements set out in the guidelines? Shoulder any other examples be used?

Yes.

10, Taken as a whole, are the guidelines practical to implement and sufficient for safe practice?

Yes.

11, Is the content flow and structure of the guideline helpful, clear, relevant and workable?

Yes.

12, Is there any content that needs to be changed or deleted?

No.

13, Is there anything missing that needs to be added?

No.

14, Do you agree with the proposed 12-month transition period and if so is this period adequate?

Yes.

15, Should the review period for guidelines be two, three or five years?

Two years.

16, Do you have any other comments on the draft guideline?

No

Thanks for providing the chance!

Mr. Zhixing Wu